The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma.
M. D. Lozano
No relevant relationships to disclose
T. Labiano
No relevant relationships to disclose
J. I. Echeveste
No relevant relationships to disclose
M. Montana
No relevant relationships to disclose
N. Gomez
No relevant relationships to disclose
M. F. Sanmamed
No relevant relationships to disclose
A. Gurpide
No relevant relationships to disclose
M. A. Idoate
No relevant relationships to disclose
S. Martin-Algarra
No relevant relationships to disclose